- Bloom Health Partners (BLMH) ended Q1 2022 with C$5.8M in revenue and $5.1M in cash
- It recorded a quarterly loss from operations of $1M due to investment in expansion and lower revenue due to cyclical factors
- It is maintaining full year revenue guidance of up to $28M
- Bloom Health Partners offers a global platform for health care security, diagnostic testing and occupational health-tech
- Bloom Health (BLMH) is unchanged trading at $0.32 per share
Bloom Health Partners (BLMH) ended Q1 2022 with C$5.8M in revenue and $5.1M in cash.
It finished the quarter on December 31st, 2021, with a loss from operations of $1M due to investment in expansion and lower revenue due to cyclical factors.
The company is maintaining 2022 revenue guidance of between $25M-$28M.
It also expects positive EBITDA from operations for the year.
“We made investments in expansion in Dallas, Atlanta and Alabama as a result of client opportunities and contracts,” stated Andrew Morton, Bloom Health’s CEO. “Our lab business and evolution with clients to operational health combined with our Bloom Shield health-tech software platform continues to show good momentum. We’re executing on our vision of keeping businesses and organizations running with operational health and health-tech.”
Bloom Health Partners offers a global platform for health care security, diagnostic testing and occupational health tech.
Bloom Health (BLMH) is unchanged trading at $0.32 per share as of 2:50 pm EST.
